| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
While primarily used as a tyrosine kinase inhibitor for certain cancers, imatinib has been investigated for its effects on B-cell receptor signaling pathways. It might indirectly influence BRDG1 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor primarily used in cancer research. It could impact B-cell receptor signaling pathways and potentially affect BRDG1-mediated processes. | ||||||
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
Apart from its Syk inhibitory effects, fostamatinib has been explored for its broader impacts on B-cell signaling, which could influence BRDG1 activity. | ||||||
Tirabrutinib | 1351636-18-4 | sc-507435 | 10 mg | $138.00 | ||
A BTK inhibitor, tirabrutinib has been investigated for its effects on B-cell signaling pathways, which could indirectly affect BRDG1-mediated processes. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
A BTK inhibitor with potential anti-inflammatory effects, ACP-196 could influence B-cell receptor signaling pathways and related proteins like BRDG1. | ||||||
TGR-1202 | 1532533-67-7 | sc-507436 | 25 mg | $286.00 | ||
This compound has been developed as a dual inhibitor of PI3K-delta and CK1-epsilon. Since PI3K signaling is closely related to B-cell receptor pathways, umbralisib could indirectly affect BRDG1-mediated processes. | ||||||